Abstract:Objective To determine the clinical value of dacryocystography for diagnosing dacryocystitis in infants and young children.Methods We conducted a retrospective analysis on clinical data of 200 infants and young children with dacryocystitis treated in our hospital from May 2022 to December 2023. All patients underwent dacryocystography, with contrast agents injected to observe lacrimal duct patency. Parameters such as length, horizontal diameter, anteroposterior diameter, and volume of the lacrimal sac were assessed. Patients were randomly assigned to the control group and the observation group using a random number table, with 100 cases in each group. The control group underwent dacryocystography based on indications, while the observation group was additionally treated with Houttuynia cordata eye drops. The therapeutic effects, recovery, and complications were compared between the two groups.Results The length of the lacrimal sac of the patients was (9.89 ± 4.69) mm, and the volume of the lacrimal sac was (0.26 ± 0.13) cm3. The overall effective rate of the observation group was higher than that of the control group (P < 0.05). The observation group showed better lacrimal duct irrigation and improvement in postoperative eye discharge compared with the control group (P < 0.05). There was no statistically significant difference in the overall incidence of adverse reactions between the two groups (P > 0.05).Conclusions Dacryocystography allows for direct observation of the patency of the lacrimal ducts and timely detection of any obstructions. The use of Houttuynia cordata eye drops during dacryocystography can significantly improve the therapeutic outcomes for dacryocystitis in infants and young children, and reduce the incidence of related complications.